178 related articles for article (PubMed ID: 36443163)
1. Modern Active Surveillance in Prostate Cancer: A Narrative Review.
Pattenden TA; Samaranayke D; Morton A; Ong WL; Murphy DG; Pritchard E; Evans S; Millar J; Chalasani V; Rashid P; Winter M; Vela I; Pryor D; Mark S; Lawrentschuk N; Thangasamy IA
Clin Genitourin Cancer; 2023 Feb; 21(1):115-123. PubMed ID: 36443163
[TBL] [Abstract][Full Text] [Related]
2. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
3. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.
van den Bergh RC; Ahmed HU; Bangma CH; Cooperberg MR; Villers A; Parker CC
Eur Urol; 2014 Jun; 65(6):1023-31. PubMed ID: 24491309
[TBL] [Abstract][Full Text] [Related]
4. A Narrative Overview of Active Surveillance for Clinically Localised Prostate Cancer.
Bates AS; Kostakopoulos N; Ayers J; Jameson M; Todd J; Lukha R; Cymes W; Chasapi D; Brown N; Bhattacharya Y; Paterson C; Lam TBL
Semin Oncol Nurs; 2020 Aug; 36(4):151045. PubMed ID: 32703714
[TBL] [Abstract][Full Text] [Related]
5. Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting.
Moore CM; King LE; Withington J; Amin MB; Andrews M; Briers E; Chen RC; Chinegwundoh FI; Cooperberg MR; Crowe J; Finelli A; Fitch MI; Frydenberg M; Giganti F; Haider MA; Freeman J; Gallo J; Gibbs S; Henry A; James N; Kinsella N; Lam TBL; Lichty M; Loeb S; Mahal BA; Mastris K; Mitra AV; Merriel SWD; van der Kwast T; Van Hemelrijck M; Palmer NR; Paterson CC; Roobol MJ; Segal P; Schraidt JA; Short CE; Siddiqui MM; Tempany CMC; Villers A; Wolinsky H; MacLennan S
Eur Urol Oncol; 2023 Apr; 6(2):160-182. PubMed ID: 36710133
[TBL] [Abstract][Full Text] [Related]
6. Advances in the selection of patients with prostate cancer for active surveillance.
Liu JL; Patel HD; Haney NM; Epstein JI; Partin AW
Nat Rev Urol; 2021 Apr; 18(4):197-208. PubMed ID: 33623103
[TBL] [Abstract][Full Text] [Related]
7. Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.
Venderbos LD; Roobol MJ; Bangma CH; van den Bergh RC; Bokhorst LP; Nieboer D; Godtman R; Hugosson J; van der Kwast T; Steyerberg EW
World J Urol; 2016 Feb; 34(2):253-60. PubMed ID: 26160006
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance for prostate cancer: past, present and future.
Singer EA; Kaushal A; Turkbey B; Couvillon A; Pinto PA; Parnes HL
Curr Opin Oncol; 2012 May; 24(3):243-50. PubMed ID: 22450149
[TBL] [Abstract][Full Text] [Related]
9. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
10. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
11. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
12. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
13. Active Surveillance of Prostate Cancer Using Multiparametric Magnetic Resonance Imaging: A Review of the Current Role and Future Perspectives.
Sklinda K; Mruk B; Walecki J
Med Sci Monit; 2020 Apr; 26():e920252. PubMed ID: 32279066
[TBL] [Abstract][Full Text] [Related]
14. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
15. [Optimization of follow up in prostate cancer active surveillance].
Celma Domènech A; Planas Morin J; Morote Robles J
Arch Esp Urol; 2014 Jun; 67(5):442-51. PubMed ID: 24914843
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
Aminsharifi A; Simon R; Polascik TJ; Robertson CN; Sudan DL; Collins BH; Moul JW
J Urol; 2019 Sep; 202(3):469-474. PubMed ID: 30835631
[TBL] [Abstract][Full Text] [Related]
17. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance in prostate cancer: a critical review.
Zargar H; Giannarini G; Loeb S; Dasgupta P; Murphy DG; Ficarra V
Minerva Urol Nefrol; 2015 Sep; 67(3):247-61. PubMed ID: 26054412
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
[TBL] [Abstract][Full Text] [Related]
20. Active surveillance in men with localized prostate cancer: a systematic review.
Dahabreh IJ; Chung M; Balk EM; Yu WW; Mathew P; Lau J; Ip S
Ann Intern Med; 2012 Apr; 156(8):582-90. PubMed ID: 22351515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
